The prevalence and burden of Rome IV bowel disorders of gut brain interaction in patients with non-alcoholic fatty liver disease: a cross-sectional study
暂无分享,去创建一个
D. Vasant | V. Athwal | K. Hanley | Lucy Bennett | H. Purssell | Oliver Street | N. Hanley
[1] P. Whorwell,et al. The national prevalence of disorders of gut brain interaction in the United Kingdom in comparison to their worldwide prevalence: Results from the Rome foundation global epidemiology study , 2023, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[2] O. Palsson,et al. Epidemiology of disorders of gut‐brain interaction in Belgium and differences between two language groups: Results from the Rome foundation global epidemiology study , 2023, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[3] Shengtao Zhu,et al. Non-alcoholic fatty liver is associated with increased risk of irritable bowel syndrome: a prospective cohort study , 2022, BMC Medicine.
[4] P. Whorwell,et al. The symptom burden of Irritable Bowel Syndrome in tertiary care during the COVID‐19 pandemic , 2022, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[5] P. Whorwell,et al. Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence? , 2021, World journal of hepatology.
[6] J Zhang,et al. 2019 global NAFLD prevalence - A systematic review and meta-analysis. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[7] A. Ford,et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome , 2021, Gut.
[8] V. Athwal,et al. Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications , 2021, Current Diabetes Reports.
[9] E. Savarino,et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. , 2020, The lancet. Gastroenterology & hepatology.
[10] H. Tilg,et al. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications , 2020, Gut.
[11] B. Hanratty,et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies , 2020, PLoS medicine.
[12] P. Whorwell,et al. Stigma and irritable bowel syndrome: a taboo subject? , 2020, The lancet. Gastroenterology & hepatology.
[13] G. K. Beyera,et al. Health-care utilisation for low back pain: a systematic review and meta-analysis of population-based observational studies , 2019, Rheumatology International.
[14] M. Zamani,et al. Systematic review with meta‐analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome , 2019, Alimentary pharmacology & therapeutics.
[15] J. Walters,et al. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study , 2019, PloS one.
[16] R. Malekzadeh,et al. A Comprehensive Look at Irritable Bowel Syndrome and its Associated Factors Considering the Rome IV Criteria: A Penalized Smoothly Clipped Absolute Deviation Regression Approach in the Pars Cohort Study , 2018, Middle East journal of digestive diseases.
[17] Mark Hudson,et al. Guidelines on the management of abnormal liver blood tests , 2017, Gut.
[18] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[19] D. Rodríguez-Sanz,et al. Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.
[20] A. Ford,et al. Irritable Bowel Syndrome and Microscopic Colitis: A Systematic Review and Meta-analysis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[21] K. LevineGlenn,et al. Infections and Asthma in the Pediatric Intensive Care Unit: Prevalence and Contribution to Disease Severity , 2016 .
[22] P. Whorwell,et al. Faecal incontinence—the hidden scourge of irritable bowel syndrome: a cross-sectional study , 2014, BMJ open gastroenterology.
[23] G. Tarantino,et al. What does irritable bowel syndrome share with non-alcoholic fatty liver disease? , 2013, World journal of gastroenterology.
[24] P. Bhuyan,et al. Profile of patients with incidentally detected nonalcoholic fatty liver disease (IDNAFLD) in coastal eastern India. , 2013, Tropical gastroenterology : official journal of the Digestive Diseases Foundation.
[25] S. Calloway. More than coincidence. , 2013, Journal of Christian nursing : a quarterly publication of Nurses Christian Fellowship.
[26] Pedagógia,et al. Cross Sectional Study , 2019 .
[27] T. Therneau,et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.
[28] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[29] N. Tannenwald. A taboo subject , 2006 .
[30] M Dixon-Woods,et al. Medical and lay views of irritable bowel syndrome. , 2000, Family practice.
[31] P. Whorwell,et al. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress , 1997, Alimentary pharmacology & therapeutics.
[32] T. P. Giddings. Tests , 1928 .
[33] S. Abdel-Aal,et al. Nonalcoholic fatty liver disease among patients with irritable bowel syndrome: Prevalence and contribution to disease severity , 2018 .
[34] Lin Chang,et al. Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians. , 2016, Gastroenterology.
[35] M. Blachier,et al. Report Title: The burden of liver disease in Europe: a review of available epidemiological data , 2013 .
[36] V. Preedy,et al. Prospective Cohort Study , 2010 .
[37] Y. Katayama. Bowel disorders. , 1990, Postgraduate medicine.